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Human cancer cells operate a variety of effective molecular and signaling mechanisms
which allow them to escape host immune surveillance and thus progress the disease. We
have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9
are involved in the immune escape of human acute myeloid leukemia (AML) cells. These
cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich
transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway.
We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune
escape of cancer cells of different origins. We found that studied breast tumors expressed
significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues
of the same patients and that these proteins were co-localized. Increased levels of LPHN2
and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells.
Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell
surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based
galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced
death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast
cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3
and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms
and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range
of human cancer cells and is possibly involved in prevention of anti-tumor immunity.
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INTRODUCTION
Human malignant tumors have developed a variety of
biochemical mechanisms which allow them to escape host
immune surveillance, thus leading to disease progression
(1, 2). This applies to both liquid and solid tumors (1). It has
recently become evident that acute myeloid leukemia (AML)
cells, originating from self-renewing myeloid haematopoietic
precursors, operate an immunosuppressive pathway which
includes facilitation of exocytosis of the T cell immunoglobulin
and mucin domain containing protein 3 (Tim-3) and its natural
ligand, galectin-9 (2–4). Galectin-9 is a tandem protein which
contains two ligand-binding domains fused together by a peptide
linker (several isoforms have been identified) (5). As with other
galectins, galectin-9 lacks a secretory domain and thus requires
trafficking in order to be translocated onto the cell surface
where it could be secreted by proteolytic shedding (5). Tim-3
acts both as a receptor and a possible trafficker for galectin-9
(2, 4, 6). When associated with the plasma membrane, the Tim-
3-galectin-9 complex triggers downstream signaling contributing
to cell renewal, thus forming an autocrine loop (6). On the other
hand, proteolytic shedding results in release of both a soluble
form of Tim-3 and galectin-9 (2). Both Tim-3 and galectin-9
act to suppress anti-cancer immune surveillance (2). Secreted
galectin-9 contributes to anti-cancer immune suppression by
killing cytotoxic T lymphocytes and impairing the activity of
natural killer (NK) cells, thus allowing for disease progression
(2, 4). Soluble Tim-3 also downregulates the production of
interleukin-2 (IL-2), a cytokine required for the activation of
both NK cells and cytotoxic T lymphocytes (2).
AML cells express the G-protein coupled neuronal receptor
latrophilin 1 (LPHN1) which is produced by haematopoietic
stem cells (HSCs) but disappears upon their maturation (7,
8). In case that HSCs undergo malignant transformation, thus
becoming AML cells, they preserve the ability to express LPHN1
(7, 8). Interacting with its natural ligand, fibronectin leucine rich
transmembrane protein 3 (FLRT3) and possibly other ligands (2,
3), LPHN1 facilitates translocation of Tim-3 and galectin-9 onto
the cell surface via GαQ [G protein transducing the signal from
LPHN (7)]—phospholipase C (PLC)—protein kinase C alpha
(PKCα) biochemical pathway, which is followed by proteolytic
shedding of the complex or ligand-free Tim-3 (2), creating an
immune suppressive “double edged sword.” Translation of Tim-
3 and galectin-9 in these cells is controlled by the mammalian
target of rapamycin (mTOR) pathway (2), one of the master
regulators of protein biosynthesis.
Interestingly, other LPHN isoforms, in particular LPHN2,
were found to be ubiquitously expressed especially in breast
tumors (9). Human breast tumor cells were also found to express
galectin-9, where it was shown to be involved in cell aggregation,
thus preventing metastasis (10). On the other hand, the Tim-3-
galectin-9 pathway plays a role in suppressing cytotoxic T cells
in solid tumors, for example in colon cancer (11). However, the
biochemical events underlying these processes have not been
studied yet and it is therefore important to investigate whether
the activity of the Tim-3-galectin-9 secretory pathway is specific
solely to AML cells or whether it is also common for breast
and other solid tumors. This will help us to understand the
fundamental pathophysiological role of the pathway and its
underlying biochemistry.
Therefore, the aim of our work was to investigate the
biochemical activity of the Tim-3-galectin-9 pathway in human
breast cancer and its possible role in suppressing cytotoxic T cell
activity. In addition, we assessed the differential expression of
the components of the Tim-3-galectin-9 pathway in human solid
tumor cells.
Here we report that primary breast tumors express
significantly higher levels of Tim-3, and especially galectin-
9, compared to healthy tissues of the same patients. Importantly,
Tim-3 and galectin-9 were co-localized. Breast tumors also
expressed LPHN2 and LPHN3 as well as FLRT3. The PLC/PKC
secretory biochemical pathway was significantly upregulated in
breast tumors compared to healthy tissues. Breast cancer cell
lines expressed all these components and biochemical studies
were conducted using MCF-7 cells. Breast cancer cells were
unable to secrete galectin-9, but were capable of maintaining
its cell surface expression. The process of externalization was
upregulated by exogenous FLRT3 most likely in a PLC/PKC-
dependent manner. Surface-based galectin-9 was able to protect
MCF-7 cells against T cell-induced death. Furthermore, we
found that human cell lines originating from a wide range of
different cancers express detectable amounts of both Tim-3 and
galectin-9 proteins. The majority of these cell lines expressed at
least one of the LPHN isoforms as well as FLRT3, suggesting that
various types of solid and liquid tumors can in principle operate
the FLRT3/LPHN/Tim-3/galecting-9 pathway.
MATERIALS AND METHODS
Materials
RPMI-1640 medium, fetal bovine serum and supplements as
well as basic laboratory chemicals were purchased from Sigma
(Suffolk, UK). Maxisorp
TM
microtitre plates were provided
either by Oxley Hughes Ltd (London, UK) or Nunc (Roskilde,
Denmark). Mouse monoclonal antibodies directed against
mTOR and β-actin, as well as rabbit polyclonal antibodies
against phospho-S2448 mTOR, galectin-9, HRP-labeled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Mouse monoclonal antibody against FLRT3
was obtained from Santa Cruz Biotechnology (Heidelberg,
Germany). Antibodies against phospho-S65 and total eIF4E-
BP were obtained from Cell Signaling Technology (Danvers,
MA USA). The polyclonal rabbit anti-peptide antibodies (PAL1,
PAL2, and PAL3) against LPHN1, LPHN2, and LPHN3,
respectively, were previously described (12). Rabbit polyclonal
antibody against poly-(ADP-ribose)-polymerase (PAR) was
purchased from Enzo Life Sciences LTD (Exeter, UK). Goat anti-
mouse and goat anti-rabbit fluorescence dye-labeled antibodies
were obtained from LI-COR (Lincoln, Nebraska USA). ELISA
kits for the quantitation of galectin-9, Tim-3, and IL-2 were
purchased from Bio-Techne (R&D Systems, Abingdon, UK).
Anti-Tim-3 mouse monoclonal antibody was employed as
previously described (13). Secondary antibodies for confocal laser
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microscopy (TRITC labeled antibody (goat anti-mouse IgG) and
t FITC labeled antibody (goat anti-rabbit IgG) were from Abcam
(Cambridge, UK). All other chemicals purchased were of the
highest grade of purity.
Cell Lines and Primary Human Cells
Cell lines, listed in Supplementary Table 1, were obtained from
either European Collection of Cell Cultures, American Tissue
Culture Collection (ATTC) or CLS Cell Lines Service GmbH.
Cell lines were accompanied by identification test certificates and
were grown according to corresponding tissue culture collection
protocols. LAD2mast cells were kindly provided by ProfMetcalfe
andDr. Kirshenbaum (NAID, NHI, USA) and cultured according
to the protocol described before (14).
MCF-7 breast cancer cells were purchased from the European
Collection of Cell Cultures (the cell lines provided were
accompanied by identification test certificates). Cells were
cultured in RPMI 1640 media supplemented with 10% fetal
bovine serum, penicillin (50 IU/ml), and streptomycin sulfate
(50 µg/ml).
TALL-104 cytotoxic T lymphocytes derived from human
acute lymphoblastic leukemia (TALL) were purchased from
the American Tissue Culture Collection. Cells were cultured
according to the ATCC instructions. Briefly, ATCC-formulated
Iscove’s Modified Dulbecco’s Medium was used. To make the
complete growth medium we added 100 units/ml recombinant
human IL-2; 2.5µg/ml human albumin; 0.5µg/ml D-mannitol
and fetal bovine serum to a final concentration of 20%. Primary
human leukocytes (PHL) were isolated from buffy coat blood
(originated from healthy donors though routine blood donation).
The buffy coat blood was obtained from the National Health
Blood and Transfusion Service (NHSBT, UK) following ethical
approval (REC reference: 16-SS-033).
Human Tissue Samples
Primary human tumor tissue samples paired together with
peripheral tissues (also called “normal” or “healthy” of the same
patients) were collected surgically from breast cancer patients
treated at the Colchester General Hospital, following informed,
and written consent taken before surgery. Paired normal
(healthy) peripheral tissues were removed during macroscopic
examination of a tumor by pathologists. Blood samples were
collected before breast surgery from patients with primary breast
cancer (PBC) and before treatment from patients with metastatic
breast cancer (MBC). Samples were also collected from healthy
donors (individuals with no diagnosed pathology), which were
used as control samples. Blood separation was performed using
buoyancy density method employing Histopaque 1119-1 (Sigma,
St. Louis, MO) according to the manufacturer’s protocol. Ethical
approval documentation for these studies was obtained from the
NRES Essex Research Ethics Committee and the Research &
Innovation Department of the Colchester Hospitals University,
NHS Foundation Trust [MH 363 (AM03) and 09/H0301/37].
Western Blot Analysis
The components of the Tim-3, galectin-9, FLRT3, LPHNs 2/3,
and mTOR pathways as well as GαQ, PARP, and CD3 were
detected in cell and tissue lysates byWestern blot and normalized
to β-actin levels in order to confirm equal protein loading as
reported earlier (2). Cells were lysed in 50mM Tris–HCl, 5mM
EDTA, 150mM NaCl, 0.5% Nonidet-40, 1mM PMSF, pH 8.0.
Tissue lysates for Western blot analysis were prepared as
described previously (15). Briefly, 100mg of frozen tissues were
grounded into a powder in dry ice, followed by the addition
of 100 µl of the tissue lysis buffer (20mM Tris/HEPES pH
8.0, 2mM EDTA, 0.5M NaCl, 0.5% sodium deoxycholate,
0.5% Triton X-100, 0.25M Sucrose, supplemented with 50mM
2-mercaptoethanol, 50µM PMSF, 1µM pepstatin supplied
just before use). Tissues were homogenized using a Polytron
Homogenizer (Capitol Scientific, USA) and a syringe was used
in order to acquire a homogenous cell suspension. These tissue
suspensions were then filtered through medical gauzes and
centrifuged at +4◦C at 10,000 g for 15min. Proteins present in
supernatants were precipitated by incubation of the samples on
ice for 30min with equal volumes of ice-cold acetone. Protein
pellets were obtained by centrifugation at +4◦C, 10,000 g for
15min followed by air drying at room temperature and then lysed
using the SDS-lysis buffer described above.
Li-Cor goat secondary antibodies (dilution 1:2,000),
conjugated with infrared fluorescent dyes, were used as
described in the manufacturer’s protocol to visualize target
proteins (Li-Cor Odyssey imaging system was applied). Western
blot data were quantitatively analyzed using Odyssey software
and values were subsequently normalized against those of β-actin
or total protein loaded.
Enzyme-Linked Immunosorbent
Assays (ELISAs)
Galectin-9, soluble Tim3 (sTim-3) and IL-2 were measured by
ELISA using R&D Systems kits according to manufacturer’s
protocols. Phosphorylation of mTOR was analyzed by ELISA as
previously described (16).
ELISA was also used to detect Tim-3-galectin-9 complex as
described before (4) in the tissue homogenates. Homogenates
were prepared in the ratio 1 g of tissue and 4ml of lysis
(extraction) buffer containing 50mMTris pH 7.5, 150mMNaCl,
5mM EDTA, and 0.5% NP-40. Mouse anti-Tim-3 (mAnti-Tim-
3) was used as a capture antibody and biotinylated goat anti-
galectin-9 (gAnti-Galectin-9, R&D Systems) for detection. The
reaction was visualized using HRP-labeled streptavidin (R&D
Systems; Figure 2A—see the scheme). In all cases plates were
washed with TBST and bound secondary antibodies visualized
using peroxidase reaction (ortho-phenylenediamine/H2O2).
Quantitative Real-Time PCR (qRT-PCR)
To detect galectin-9 mRNA levels, we used qRT-PCR (4).
We isolated total RNA using a GenElute
TM
mammalian total
RNA preparation kit (Sigma-Aldrich), followed by reverse
transcriptase–polymerase chain reaction (RT-PCR) of a target
protein mRNA (performed according to the manufacturer’s
protocol). This was followed by qRT-PCR. The following primers
were used: Galectin-9, 5′-CTTTCATCACCACCATTCTG-3′ and
5′-ATGTGGAACCTCTGAGCACTG-3′ actin, 5′-TGACGGGG
TCACCCACACT-GTGCCCATCTA-3′, 5′-CTAGAAGCATTT
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GCGGTCG-ACGATGGAGGG-3′. Reactions were performed
using a LightCycler R© 480 qRT-PCR machine and SYBR Green I
Master kit (obtained from Roche, Burgess Hill, UK). The work
was performed according to the manufacturer’s protocol. Values
representing galectin-9 mRNA levels were normalized against
those of β-actin.
On Cell Assays
On cell assays were employed to detect surface presence of
galectin-9 and CD8. We used Li-Cor secondary antibody to
recognize anti CD8 primary antibody and then visualized as
described before (4, 17).
Confocal Microscopy
Tissue Sectioning
Tissue sections were produced using a freezing microtome with
the cutting thickness of 5–6µm. Each tissue section was sliced
onto a poly-D-lysine-coated microscope slide (BDH).
Immunofluorescence Staining for Bioimaging
Analysis
Endogenous peroxidase activity was blocked by incubating
slides in 3% in H2O2 for 15min. The slides were then
permeabilised using PBS containing 0.26% Triton for 20min
at room temperature and blocked with serum obtained from
the same species as the secondary antibody in the following
buffer: PBS, 0.05% Tween, 2% serum, 1% BSA for at least 30min.
Tim-3 and galectin-9 expressions were detected by incubating
slides with antibodies described above diluted in PBS (pH 7.4
containing 0.05% Tween, 1% BSA (1:200 dilution) for 2 h at
room temperature and washed three times with PBS. Slides
were then incubated in the dark for 1 h with anti-IgG-FITC-
labeled secondary antibody (1:400 dilution) and then washed
three times with PBS followed by Fluoro-Gel mounting media
containing DAPI nuclei-staining reagent. Negative controls were
prepared by incubating the slides with secondary antibody alone.
Images were taken using Confocal Laser Scanning Microscopy
(BioRad Hercules).
Fluorescence Co-localization Imaging
For image acquisition, a Nikon A1si laser scanning confocal
microscope was used with a Plan Fluor DIC 40x magnifying,
1.3-numerical aperture (N.A.) oil-immersion objective. NIS
Elements software (version 3.21.03, Nikon, Tokyo, Japan) was
employed for data analysis. Cell images were acquired in
three channels for DAPI (excitation at 399 nm with laser
power 10 arbitrary units [AU], emission collection at 450 nm;
nuclei labeling), Alexa Fluor 488 (excitation wavelength 488 nm
with laser power 10AU and, emission wavelength at 525 nm
(corresponds to a green channel, galectin-9), Alexa Fluor 555
(excitation 561 nm with laser power 10AU, emission collection
at 595 nm, red channel, Tim-3), with a photomultiplier tube gain
of 100AU. No offset was used, and pinhole size was set between
1.2 and 2 times the Airy disk size of the used objective, depending
on signal strength.
PLC and PKCα Activity Assays
The activity of PLC was measured based on the ability of
this enzyme to cleave the ester bond between glycerol and
phosphoric acid of the substrate phosphatidylinositol-4,5-bis-
phosphate (PIP2). PIP2 (150µM), was re-suspended in the assay
buffer containing 20mM Tris-HCl buffer (pH 7.2) containing
0.1% sodium deoxycholate, 300µM CaCl2, 100µM EDTA,
and 100mM NaCl by sonication. Reaction was started by
adding the substrate followed by incubation for 60min at
37◦C. Uncleaved substrate and IP3 (the reaction product) were
then measured using electrophoretic (33% polyacrylamide gel)
separation, followed by toluidine blue staining and colorimetric
assay (13, 18). The catalytic activity of PKCα was measured
as described before based on its ability to phosphorylate
specific substrate in a reaction buffer containing 20mM Tris-
HCl (pH7.5), 20µM ATP, 5mM MgCl2, and 200µM CaCl2
(19). Phosphate groups attached to the substrate were detected
spectrophotometrically (20).
Cell Viability Assay
Cell viability was analyzed using a commercial assay kit (Promega
UK Ltd., Southampton, UK). We used an MTS colorimetric
assay for assessing cell metabolic activity. NAD(P)H-dependent
cellular oxidoreductase enzymes playing a crucial role in human
myeloid cell survival reflect the number of viable cells present.
Cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) and then absorbance was measured at 490 nm in
accordance with the manufacturer’s protocol.
Synchrotron Radiation Circular Dichroism
(SRCD) Spectroscopy
Human recombinant LPHN2 (olfactomedin-like domain,
MyBioSource, San Diego, CA, USA) and FLRT3, either alone or
in combination (equimolar ratio), were analyzed using SRCD
spectroscopy at beamline B23, Diamond Light Source (Didcot,
UK) (3, 21, 22). SRCD measurements were performed using
0.7µM of samples in a 1 cm path length cell of 3mm aperture
diameter and 60 µl capacity using a Module B instrument
at 23◦C. Integration time was 1 s, the increment−1 nm and
bandwidth−1.2 nm. The results obtained were processed using
CDApps and OriginPro R©.
Statistical Analysis
Each experiment was performed at least three times and statistical
analysis when comparing two events at a time was conducted
using a two-tailed Student’s t-test. Multiple comparisons were
performed using ANOVA. Post-hoc Bonferroni correction was
applied. Statistical probabilities (p) were expressed as ∗ for p <
0.05; ∗∗ for p < 0.01, and ∗∗∗ for p < 0.001.
RESULTS
Expression and Activity of the
FLRT3/LPHN/Tim3/galectin-9 Pathway in
Breast Tumors
We found that primary breast tumors expressed galectin-9, Tim-
3, LPHN2, and FLRT3 (Figures 1A,B); as well as detectable
amounts of LPHN3 (Supplementary Figure 1). Interestingly, in
addition to a specific FLRT3 bands, a clear band appears at
around 55 kDa (highlighted by a question mark). This may
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FIGURE 1 | Expression of FLRT3/LPHN/Tim-3/galectin-9 pathway components and activities of PLC/PKCα and mTOR pathways in primary human breast tumors.
Expression levels of Tim-3, galectin-9 (A), FLRT3, and LPHN2 (B) were analyzed in primary breast malignant tumors and healthy breast tissues (HT) of five patients
(n = 5) by Western blot. Activities of PLC, PKCα, and the levels of phospho-S2448 mTOR were detected as outlined in the Materials and Methods (C). The amounts
of phospho-S65 and total eIF4E-BP (mTOR substrate) were analyzed using Western blot (D). The levels of CD3 (biomarker of T cells) were also measured using lysate
of Jurkat T cells as a positive control (E). Molecular weight markers (MW) are expressed in kDa. Images are from one experiment representative of five which gave
similar results. Other results are shown as mean values ± SEM. *p < 0.05; **p < 0.01, and ***when p < 0.001 vs. control.
represent FLRT3 which underwent proteolytic processing (3).
Importantly, expression levels of Tim-3, galectin-9 and LPHN2
were significantly higher (about 15–20 fold for galectin-9, p <
0.001, 2 fold for Tim-3, p < 0.05 and 2.5–3 fold for LPHN2,
p < 0.01) in tumors compared to healthy tissues isolated from
the same patients. A band specific for galectin-9 appeared at
around 55 kDa when 12% PAGE was used (this is the gel
concentration normally used for galectin-9 detection) in each
case and was not detectable by the anti-Tim-3 antibody. This
indicates that this band is not the Tim-3-galectin-9 complex
but probably a galectin-9 isoform bound to carbohydrates (as
a lectin) which is unlikely to be secreted. This was confirmed
when the same sample was ran using 10% PAGE and the
specific band appeared above 31 kDa molecular weight marker
(Supplementary Figure 2) confirming that, in a 12 % gel, protein
running was “delayed” possibly due to the presence of glycosides
or other post-translational modifications affecting the protein
properties/shape but not the molecular weight. Activities of PLC
and PKCα were significantly higher (p < 0.01 for PLC and p
< 0.001 for PKCα) in tumor tissue homogenates compared to
those of healthy tissues (Figure 1C). However, unlike in AML
cells (2), the S2448 phosphorylation level of mTOR was similar in
both healthy and tumor tissues (Figure 1C). The ratio between
phospho-S65 eIF4E-BP and its total amount was also similar in
both tissue types, although the amount of both phospho-S65 and
total eIF4E-BP was higher in tumor tissues (Figure 1D).
Importantly, analysis of CD3 (a marker of T cells)
demonstrated that this protein is undetectable in healthy
and barely detectable in tumor tissue lysates suggesting that the
analyzed proteins are mainly expressed by breast tumor cells and
not tumor-infiltrated lymphocytes (Figure 1E).
In order to assess if Tim-3 is complexed to galectin-9 as in
leukemia cells, we performed detection of the Tim-3-galectin-9
complex in tissue homogenates as outlined in the Materials and
Methods. We found that the complex was barely detectable in
normal tissue homogenates but was clearly detectable in tumor
tissue extracts (Figure 2A). Next, measurement of Tim-3 and
galectin-9 in tissues was performed using confocal microscopy.
In line with the data shown in Figures 1, 2A, we observed
that both proteins are abundant in tumor tissue slices and are
also co-localized (Figure 2B). Analysis of blood plasma samples
obtained from patients with both primary and metastatic breast
tumors showed that levels of galectin-9 and soluble Tim-3 were
lower compared to healthy donors (Figure 3). Respectively, both
patient groups demonstrated non-significantly higher levels of
IL-2 (Figure 3).
MCF-7, BC-8701, and MDA-MB-231 breast cancer cells
(Supplementary Table 1 and Supplementary Figure 1) all
expressed Tim-3, galectin-9, FLRT3, and at least one LPHN
isoform. The highest level of LPHN2was expressed byMDA-MB-
231 cells, which is in line with previously reported observations
(9). To further investigate the mechanism we selected MCF-7
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FIGURE 2 | Expression, interaction, and co-localization of Tim-3 and galectin-9 in primary human breast tumors. (A) Presence of the Tim-3-galectin-9 complex in
primary normal and tumor tissue extracts was analyzed using ELISA as outlined in the Materials and Methods. (B) Expression and co-localization of galectin-9 and
Tim-3 were analyzed in primary human breast tumors and healthy tissues of the same patients using confocal microscopy (see Materials and Methods for further
details). Images are from one experiment representative of five which gave similar results. Scale bars correspond to 20µm.
FIGURE 3 | Levels of galectin-9, Tim-3, and IL-2 in blood plasma of human healthy donors and patients suffering from primary and metastatic breast tumors.
Concentrations of galectin-9, soluble Tim-3, and IL-2 were analyzed in blood plasma of healthy donors and breast cancer patients by ELISA. Data are shown as mean
values ± SEM of 20 for healthy donors (HD), 42 for primary breast cancer (PBC) patients, and 20 for metastatic breast cancer (MBC) patients. *p < 0.05; **p < 0.01
and vs. HD.
breast cancer cells since they are the only cell line analyzed
which expressed detectable amounts of both LPHNs 2 and 3
(as in primary breast tumors, Supplementary Figures 1A,C).
They also expressed Tim-3 and galectin-9 (Tim-3-galectin-9
complex was also detectable, Figure 4A). Galectin-9 mRNA
levels in MCF-7 cells were also significantly higher compared
to normal human breast tissue (Supplementary Figure 1B).
The level of galectin-9 mRNA in primary human breast
tumor tissues was much higher compared to the normal tissue
(Supplementary Figure 1B) and, importantly, the ratio of
galectin-9 mRNA in tumor and normal tissues was similar to
the respective levels of protein detected (Figure 1A). Also these
results suggest that MCF-7 cells as well as primary healthy and
malignant cells express identical galectin-9, thus re-confirming
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FIGURE 4 | FLRT3 induces translocation of galectin-9 onto the surface of MCF-7 breast cancer cells. (A) MCF-7 cells were exposed for 4 h to 10 nM FLRT3 and
activities of PLC, PKCα, the levels of phospho-S2448 mTOR and the amounts of phospho-S65 and total eIF4E-BP (an mTOR substrate) were analyzed as described
in the Materials and Methods. (B) MCF-7 cells were exposed for 4 h to 10 nM FLRT3 with or without 1 h pre-treatment with 30µM U73122 (PLC inhibitor) or 70 nM
Gö6983 (PKCα inhibitor). Surface presence of galectin-9 was measured by on-cell assay. (C) Secondary structure and conformational changes of LPHN2
olfacomedin-like domain (FLRT3-inding region), FLRT3, and the complex of the two proteins mixed at the equimolar ratio were characterized using SRCD
spectroscopy as outlined in the Materials and Methods. An interaction between olfactomedin-like domain of LPHN3 and FLRT3 generated by Swiss PDB viewer
[5 cmn.pdb file downloaded through PubMed database was used (13)] is presented to illustrate the structural basis of this interaction. Images are from one experiment
representative of four which gave similar results. Other results are shown as mean values ± SEM of at least three independent experiments. *p < 0.05; **p < 0.01 vs.
control.
that the same protein was detected by Western blot (Figure 1
and Supplementary Figure 1A).
LPHN2 expression in MCF-7 cells was lower than in MDA-
MB-231 but comparable with primary tumors. Furthermore,
primary breast tumors and MCF-7 cells expressed comparable
amounts of LPHN3 (Supplementary Figure 1C). It is important
to mention that there are possible minor variations in LPHN2
gene in breast cancer cells lines (23) and possibly in primary
breast tumors, however the translated protein has no variations
in amino acid sequence. Both primary breast tumor and
MCF-7 cells expressed GαQ (Supplementary Figure 1D), which
indicates the presence of an adaptor protein required for
transduction of signals via G-protein-coupled receptors (LPHN
isoforms). Cells were also exposed for 4 h to 10 nM human
recombinant FLRT3 followed by detection of phospho-S65/total
eIF4E-BP, phospho-S2448 mTOR, activities of PLC and PKCα as
well as cell surface presence of galectin-9. As shown in Figure 4A,
exposure to FLRT3 did not affect mTOR activity but significantly
upregulated the activities of PLC and PKCα. Galectin-9 surface
presence was also significantly upregulated as measured by on-
cell assay (Figure 4B). Importantly, pre-treatment of the cells
for 1 h with 30µM U73122 (PLC inhibitor) and 70 nM Gö6983
(PKCα inhibitor) before 4 h exposure to 10 nM FLRT3 attenuated
FLRT3-induced galectin-9 translocation onto the cell surface
(Figure 4B). This confirms that FLRT3-induced translocation of
galectin-9 onto the surface of MCF-7 cells is controlled by the
PLC/PKCα pathway.
To further verify the interaction of FLRT3 with the
olfactomedin-like domain of LPHN2 [for LPHNs 1 and 3 this
has already been confirmed (3, 24–26)] we performed SRCD
spectroscopy analyzing spectra (thus characterizing secondary
structure and conformational changes) of the olfactomedin-
like domain of LPHN2 and FLRT3 alone and their equimolar
combination. We found that binding of FLRT3 took place in a
similar fashion as previously reported for LPHN1 (Figure 4C).
This suggests that all three LPHN isoforms interact with FLRT3
in a similar way (a 3D interaction of LPHN3 oflactomedin-like
domain and FLRT3 is presented in Figure 4C).
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Galectin-9 Protects Breast Cancer Cells
Against Cytotoxic Immune Attack
To assess the effect of galectin-9 in protecting breast cancer cells
against cytotoxic cell-dependent killing we co-cultured MCF-
7 cells (adherent) with cytotoxic ALL-derived TALL-104 CD8-
positive T lymphocytes (we used these rather than NK cells since
mainly T cells infiltrate solid tumors; as NK cells, TALL-104 cells
express Tim-3, and not galectin-9) for 16 h at a ratio of 4 MCF-
7 cells: 1 TALL-104 cells (Figure 5A—this ratio was selected
experimentally to achieve moderate effects in order to be able to
trace biochemical mechanisms). The co-culture was performed in
either the absence or presence of 5µg/ml galectin-9 neutralizing
antibody to evaluate the contribution of surface-based galectin-
9. Following the treatment TALL-104 cells were collected, lysed,
and subjected to Western blot analysis of full-length and cleaved
PARP (marker of apoptosis). We found that in TALL-104 cells
co-cultured with MCF-7 cells the level of PARP cleavage was
significantly (about 3 fold, p < 0.05) increased and the presence
of anti-galectin-9 antibody attenuated the effect (Figure 5B).
Increased level of PARP cleavage indicates a higher number of
apoptotic cells. An on-cell assay was used to assess the level of
infiltration of TALL-104 cells into the MCF-7 cell monolayer. We
observed that CD8 was absent in the MCF-7 cells when cultured
on their own, but it was detected when MCF-7 cells were co-
cultured with TALL-104. It was further significantly increased
when the cells were co-cultured in the presence of galectin-9
neutralizing antibody, suggesting that the ability of TALL-104
cells to attack MCF-7 cells is increased when galectin-9 activity is
disabled (Figure 5B). Isotype control antibody (used at the same
concentration of 5µg/ml) did not affect interactions between
TALL-104 and MCF-7 cells, confirming the role of galectin-9 in
this process (Figure 5C). Importantly, cell surface presence of
galectin-9 was significantly upregulated in the presence of TALL-
104 cells as measured by the on-cell assay (Figure 5D). Similar
effect was observed before in other solid tumors (27). Viability of
MCF-7 cells was also decreased in the presence of TALL-104 cells
and galectin-9 neutralizing antibody (but not isotype control) as
measured by an MTS test (Figure 5E). This is a strong indication
that galectin-9 is capable of protecting breast tumor cells against
cytotoxic cell-dependent killing.
The Majority of Solid and Liquid Tumors
Express Key Components of the
FLRT3/LPHN/Tim-3/galectin-9 Pathway
To investigate the expression of FLRT3/LPHN/Tim-3/galectin-
9 pathway components in cancer cells of different origins,
we screened various human cancer cell lines (derived from
brain, colorectal, kidney, blood/mast cell, liver, breast, prostate,
lung, and skin tumors) and various non-malignant cell lines
and primary cells, using Western blot analysis. Comparative
analysis was performed by measuring infrared fluorescence
of the bands divided by the total quantity of the loaded
protein. This approach was taken because the cells analyzed
originated from different tissues and thus the levels of each
housekeeping protein (such as beta-actin, for example) vary
depending on the origin of the cells. Results of quantitative
analysis are summarized in Figure 6 and Western blot images
are presented in Supplementary Table 1. Tim-3 and galectin-
9 were present in all the studied cancer cells, except for
the chronic myeloid leukemia (CML) cell line, K562, which
expressed Tim-3 but only traces of galectin-9, in agreement
with previously reported observations (2). Of note, this could
be one of the reasons why CML cells entering the circulation
are rapidly eliminated by cytotoxic lymphoid cells. As indicated
above, we also measured the levels of secreted galectin-9 in
different cells lines and observed variations dependent on
their origin (Supplementary Table 1). The highest levels of
galectin-9 were detected in hematological (except for K562
cells) and colorectal cancer cells. Other cell types expressed
moderate levels and prostate cancer cells expressed lower but
detectable levels of at least one variant of galectin-9 (Figure 6,
Supplementary Table 1). Non-malignant cells, expressed lower
amounts of galectin-9 and also Tim-3 compared to cancerous
cells of similar origins. Furthermore, the majority of the cells
expressed at least one LPHN isoform, as well as FLRT3. Some
of the cells did not express FLRT3 but expressed LPHN isoforms
(Figure 6, Supplementary Table 1). This most likely means that
LPHN expressing cells use blood-based soluble FLRT3 to trigger
the pathway since blood does not contain the other LPHN ligand
teneurin-2 (7).
DISCUSSION
The molecular mechanisms underlying the ability of cancer cells
to escape host immune surveillance remain poorly understood.
Recent evidence clearly demonstrated that some tumor cells
(AML in particular) operate the Tim-3-galectin-9 secretory
pathway which is capable of disabling cytotoxic lymphoid cells
(2, 3). However, a growing body of evidence suggests that some
solid tumors [for example colorectal tumors (11)] also express
Tim-3 and galectin-9 and use these proteins to escape host
immune attack. We studied the activity of this pathway in
breast and other solid and liquid tumors. We also investigated
the pathway in both breast tumors and healthy breast tissues
obtained from the same patients as well as in breast tumor
cell lines.
Using Western blot analysis and confocal microscopy we
found very low levels of galectin-9 in human breast tissue cells
peripheral to tumor (Figures 1, 2), which were significantly
increased in tumor cells. Importantly, as in AML cells, Tim-3, and
galectin-9 are co-localized in breast tumor cells and are capable
to form complex (Figure 2A and Supplementary Figure 1A).
However, this tumor-associated galectin-9 is unlikely to be
secreted since blood plasma levels of galectin-9 are lower than
in healthy donors. Interestingly, high levels of Tim-3 are known
to be expressed by solid tumor-infiltrating lymphocytes (27,
28), which could be used by tumor-derived galectin-9 to kill
them. Our results have confirmed that Tim-3 and galectin-9 are
expressed mainly by tumor cells, since CD3 (a T cell biomarker)
was barely detectable in tumor and undetectable in healthy
Frontiers in Immunology | www.frontiersin.org 8 July 2019 | Volume 10 | Article 1594
Yasinska et al. The Tim-3-Galectin-9 Pathway in Breast Cancer
FIGURE 5 | Galectin-9 protects MCF-7 cells against T cell-dependent cytotoxic immune attack. (A) MCF-7 cells were co-cultured with TALL-104 cytotoxic T
lymphocytes at a ratio of 4 : 1 for 16 h (the ratio was determined by the aggressive behavior of TALL-104 cells) in the absence or presence of 5µg/ml galectin-9
neutralizing antibody or 5µg/ml isotype control antibody. (B) After the experiment TALL-104 cells were lysed and PARP cleavage, as an indicator of the rate of
apoptotic cells, was measured using Western blot analysis. (C) CD8 expressions (reflecting the infiltration of TALL-104 into the MCF-7 layer) were measured by on-cell
assay. (D) Galectin-9 surface presence was measured using on-cell assay in resting MCF-7 cells and those co-cultured with TALL-104 cells (E) Viability of MCF-7 cells
was measured by MTS test. Images are from one experiment representative of five which gave similar results. Other results are presented as mean values ± SEM of
five independent experiments. *p < 0.05 vs. control.
FIGURE 6 | Expression of Tim-3, galectin-9, LPHNs 1, 2, and 3 as well as FLRT3 proteins in various human cancer cell lines. Lysates of indicated cells were
subjected to Western blot analysis as outlined in Materials and Methods (images are presented in Supplementary Table 1). Detected infrared fluorescence of the
bands divided by the total protein amounts loaded (measured using Bradford assay) was used as a measure of protein quantity. Levels of Tim-3 & total galectin-9
(A) and LPHNs 1, 2, & 3 (B) were expressed as a % of those levels present in THP-1 cells (expressed as 100%). Since THP-1 cells lack FLRT3 expression, the levels
of this protein were expressed as % RCC-FG1 (C), respectively considering FLRT3 level in these cells as 100%. Bn, brain; CR, colorectal; Ki, kidney; BBM, blood,
bone marrow and mast cells; Li, liver; Br, breast; Pr, prostate; Lu, lung; Sk, skin. Data are presented as mean values ± SEM of three independent experiments.
tissue lysates (Figure 1E). Furthermore, both proteins are co-
localized suggesting that they are expressed by the same cells
(Figure 2B). Levels of soluble Tim-3 were also downregulated
in blood plasma of breast cancer patients which is in line with
galectin-9 values. Importantly, as indicated above, our results
indicate that galectin-9 is unlikely to be secreted by breast tumors,
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since its levels do not increase in patient blood plasma and the
studied human breast cancer cell lines were incapable of secreting
galectin-9. Furthermore, the molecular weight of tissue-based
galectin-9 suggests that it is most likely associated with plasma
membrane-based glycosides, as previously described in somatic
cells (29–31). This binding would of course keep it attached to
the cell surface and prevent its release.
Taken together, these results suggest that the FLRT3/LPHN/
Tim-3/galectin-9 pathway possibly functions mainly to transfer
galectin-9 onto the cell surface rather than to secrete it as in the
case with AML cells. This would explain the lower level of mTOR
pathway activation in breast tumor cells compared to AML
cells (2), where secretion takes place and subsequently requires
replacement of the proteins through biosynthesis. Interestingly,
the findings reported here on the protein level are in line with
gene expression data for human breast cancer presented in The
Cancer Genome Atlas.
Remarkably, the level of IL-2 was non-significantly increased
in blood plasma of breast cancer patients, but not in AML
patients, including those with primary and metastatic breast
tumors. This suggests that induction of the cytotoxic activity of
NK cells and cytotoxic T cells can still take place. This observation
is supported by the fact that plasma levels of soluble Tim-3 are
also lower, since Tim-3 was shown to downregulate IL-2 secretion
by specialized T cells (2).
Tumor tissue cells expressed LPHN2 (significantly higher
levels compared to healthy tissues), LPHN3, and FLRT3 (LPHN
ligand). In line with this, the activities of PLC and PKCα were
significantly higher in tumors compared to healthy tissues. The
activity of mTOR was not upregulated, although basal levels
FIGURE 7 | Breast cancer cell-based pathobiochemical pathways showing LPHN-induced activation of PKCα, which triggers the translocation of Tim-3 and galectin-9
onto the cell surface which is required for immune escape. The interaction of FLRT3 with LPHN isoform leads to the activation of PKCα, most likely through the classic
Gq/PLC/Ca2+pathway. Ligand-bound LPHN activates Gq, which in turn stimulates PLC. This leads to phosphatidyl-inositol-bisphosphate (PIP2) degradation and
production of inositol-trisphospate (IP3) and diacylglycerol (DAG). PKCα is then activated by DAG and cytosolic Ca
2+. PKCα provokes the formation of SNARE
complexes that tether vesicles to the plasma membrane. Galectin-9 impairs the cancer cell killing activity of cytotoxic T cells (and other cytotoxic lymphocytes).
Possible (not directly confirmed) interactions of galectin-9 with glycoside component and T cell receptor (TCR)/CD8, with MHC I, and antigen are highlighted with
question mark “?” to indicate the fact that it is a hypothetic interaction, since TALL-104 cells used in the study kill tumor cells in MHC-independent manner (32).
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of the mTOR substrate (eIF4E-BP) were significantly higher in
tumor cells.
We found that exposure of MCF-7 breast cancer cells to
10 nM FLRT3 induces activation of PLC and PKCα. Recently
it has been found that FLRT3 activates the PKCα pathway via
LPHN isoforms (2). The activity of mTOR was not increased
after 4 h of exposure to FLRT3. FLRT3-induced externalization
of galectin-9 onto the cell surface was observed. This is in
line with previous observations made in AML cells where
galectin-9 secretion was shown to be triggered by LPHN in a
PKCα-dependent manner (2). Importantly, in both leukemia
(2) and MCF-7 cells FLRT-3-induced effects are moderate.
The effects observed with latrotoxin (a LPHN1 ligand) in
AML cells are much stronger compared to those of FLRT3
(2). These moderate effects indicate that they are most likely
continuous and thus keep the pathway operating in order
to protect malignant cells against cytotoxic lymphoid cells
on an ongoing basis but in a manner that does not allow
exhaustion of the cell. On the other hand, there are clearly
other pathways operated by breast cancer cells to suppress
the activity of cytotoxic immune cells. For example presence
of TALL-104 cells significantly upregulates galectin-9 surface
presence in MCF-7 breast cancer cells. Biochemical pathways
underlying this phenomenon remain to be identified. Based
on these observations, it can be concluded that the FLRT3-
LPHN-Tim-3-galectin-9 pathway is functional in other cancer
cells and in particular in breast cancer cell lines and primary
tumors. In this case, however, we do not observe a FLRT3-
LPHN-dependent activation of mTOR but rather a moderate,
yet significant, activation of PLC/PKCα. In contrast, FLRT3-
LPHN1 interactions in AML cells are capable of activating the
mTOR pathway. The biological effect of LPHN2-FLRT3 results
in the translocation of the Tim-3-galectin-9 complex onto the
cell surface but since there is no proteolytic shedding/secretion,
constant protein renewal is not required as it is in AML cells.
A scheme representing the involvement of FLRT3-LPHN and
other possible interactions in the activation of Tim-3-galectin-9
immunosuppressive pathway is shown in Figure 7. Intriguingly,
in line with our observations that galectin-9 levels in PC3 prostate
cancer cells are low compared to other cancer cells, these cells
were recently reported to be rapidly killed by TALL-104 cells used
in our work (32).
Interestingly, it has been previously reported that galectin-
9 demonstrates anti-metastatic potential in breast cancer
(10, 33). Possible reasons underlying such an activity were
suggested to be galectin-9-induced cell aggregation and reduced
adhesion of breast cancer cells to the extracellular matrix (10).
These studies support our hypothesis regarding the possible
interaction of galectin-9 with membrane-associated glycosides,
since this process is known to participate in determining the
membrane potential (30, 31, 34), which is a crucial factor
affecting cell aggregation. Importantly, as a result of alternative
splicing, galectin-9 may be present in three main isoforms
characterized by the length of the linker peptide: long (49
amino acids), medium (27 amino acids) and short (15 amino
acids) (5, 29–31, 33, 34). As one can see from the data
reported in Supplementary Table 1, some of the cell types can
express only one isoform, others two, or all three but the
biochemical reasons underlying this phenomenon remain to
be understood.
Additionally, NK cells interacting with galectin-9 on the
breast cancer cell surface may release interferon gamma (IFN-
γ) in response (2, 35) which could activate cytotoxic lymphoid
cells located in the area of the tumor microenvironment. These
cells can attack and kill malignant cells breaking off from the
tumor thus preventing their circulation and metastasis. Overall,
it appears that galectin-9 could protect the tumor which produces
it in order to evade host immune attack, but this may not
promote metastasis.
CONCLUSION
Our findings demonstrate the activity of the Tim-3-galectin-
9 biochemical pathway in breast and various other types of
human cancer cells and its possible implication in suppression
of host anti-cancer immune surveillance. This pathway can be
recommended for targeting in order to design novel anti-cancer
immunotherapeutic approaches based on inhibiting the Tim3-
galectin-9 pathobiochemical pathway thus enabling the immune
system to attack and eradicate malignant tumors.
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